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Schizophrenia has been conceived as a disorder of brain connectivity but it is unclear how this network 
phenotype is related to the emerging genetics. We used morphometric similarity analysis of magnetic 
resonance imaging (MRI) data as a marker of inter-areal cortical connectivity in three prior case-
control studies of psychosis: in total, N=187 cases and N=227 controls. We found that schizophrenia 
was associated with globally reduced morphometric similarity (MS) in all 3 studies. There was also a 
replicable pattern of case-control differences in regional MS which was significantly reduced in frontal 
and temporal cortical areas, but increased in parietal cortex, in patients with psychosis. Using prior 
data on brain-wide gene expression, we found that the cortical map of case-control differences in MS 
was spatially correlated with cortical expression of a weighted combination of genes enriched for 
neurobiologically relevant ontology terms and pathways. More specifically, genes that were normally 
over-expressed in cortical areas with reduced MS in these MRI data were significantly upregulated in 
a prior post mortem study of schizophrenia. We propose that this combination of neuroimaging and 
transcriptional data provides new insight into how previously implicated genes and proteins, as well 
as a number of unreported proteins in their vicinity on the protein interaction network, may interact 
to drive structural brain network changes in schizophrenia. 
Psychotic disorders have a lifetime prevalence of 1-3% and can be extremely debilitating (1). 
However, despite significant efforts, the brain architectural changes and biological mechanisms 
causing psychotic disorders are not yet well under-stood (2) and there has been correspondingly 
limited progress in development of new therapeutics (3). 
Magnetic resonance imaging (MRI) studies of schizophrenia have robustly demonstrated local changes 
in structure of multiple cortical areas, subcortical nuclei and white matter tracts (4). The most 
parsimonious explanation of this distributed, multicentric pattern of structural change is that 
distributed, multicentric pattern of structural change is that it reflects disruption or dysconnectivity o 
of large-scale brain networks comprising anatomically inter-connected brain areas. However, testing 
this dysconnectivity hypothesis of psychotic disorder has been constrained by the more fundamental 
challenges in measuring anatomical connectivity and brain anatomical networks in humans. The 
principal imaging methods available for this purpose are tractographic analysis of diffusion weighted 
imaging (DWI) and structural covariance analysis of conventional MRI. DWI-based tractography gener-
ally under-estimates the strength of long-distance anatomical connections, for example between 
bilateral homologous areas of cortex. Structural covariance analysis is not applicable to single subject 
analysis and its biological interpretation is controversial. 
We recently proposed a new technique known as “morpho-metric similarity mapping” (5), which 
quantifies the similarity between cortical areas in terms of multiple MRI parameters measured at each 
area and can be used to construct a whole brain anatomical network from an individual subject’s data. 
In keeping with histological results indicating that cytoar-chitectonically similar areas of cortex are 
more likely to be anatomically connected (6, 7), it was shown that morphometric similarity (MS) in the 
macaque cortex was correlated with tract-tracing measurements of axonal connectivity. Compared to 
both tractographic DWI-based networks, and structural covariance networks, MS networks indicated 
a greater proportion of connections between human cortical areas belonging to the same 
cytoarchitectonic class. Individual differences in the connectivity (or “hubness”) of cortical nodes in 
MS networks accounted for about 40% of the individual differences in IQ in a sample of 300 healthy 
young people: for example, higher verbal IQ was associated with higher degree (increased number of 
connections) of frontal and temporal cortical hubs. These results suggest that MS mapping could 
provide a useful new tool to analyse functionally relevant differences in brain anatomical networks in 
patients with psychotic disorders. 
Significance Statement 
Schizophrenia is understood to be a heritable disorder of brain network organization and its genetic 
causes are becoming clearer. Here we tried to join up Morphometric similarity was globally reduced 
in psychosis patients in three independent case-control datasets, meaning brain regions were more 
differentiated from each other in patients. Similarity was especially decreased in frontal and temporal 
regions, although there were also areas of increased similarity in the parietal cortex. This anatomical 
pattern of abnormal cortical structure was correlated with expression of genes enriched for nervous 
system development and synaptic signalling. Genes that were abnormally up-regulated in a prior post 
mortem study of schizophrenia were normally over-expressed in cortical areas with reduced similarity. 
 
 Here we used MS mapping to test the dysconnectivity hypothesis of psychosis in three independent 
case-control MRI datasets: the Maastricht GROUP study (83 cases, 68 controls), the Dublin study (33 
cases and 82 controls), and the Cobre dataset (69 cases and 77 controls); see Methods for details. We 
mapped case-control differences of MS at global and nodal levels of resolution individually in each 
dataset to assess replicability and we tested for significant differences in network organization that 
were consistent across studies. We used partial least squares (PLS) regression to test the hypothesis 
that this MRI network phenotype of psychosis was correlated with anatomically patterned expression 
of genes using data from the Allen Human Brain Atlas (AHBA). This approach was pioneered by (8, 9) 
and has already been applied in the context of disease (10, 11), for example to link synaptic genes with 
cortical thickness differences in autism (11), despite the fact that the AHBA is based on healthy brains. 
Finally we tested the more pathogenically specific hypothesis that the genes most strongly associated 
with case-control differences in MS were enriched for genes that have been ontologically linked to 




71 Case-control differences in global morphometric similarity. MS was globally reduced (on average 
over all brain regions) in cases compared to controls in all three datasets (Figure S2). This means that 
cortical areas were more differentiated from each other, implying that they were less connected to 
each other, in patients with psychosis compared to non-psychotic controls. The MS of each of 308 
regional nodes to the rest of the brain, or regional MS, had an approximately Normal distribution and 
in all three datasets there was a significant difference between cases and controls in the distribution 
of regional MS (P < 0.001, Kolmogorov-Smirno˙ test). Modal values of regional MS were more frequent, 
and extreme values were less frequent, in cases compared to controls (Figure S2). 
Case-control differences in regional morphometric similarity. 
The cortical map of regional MS summarises the anatomical distribution of areas of positive and 
negative similarity on average over all controls from all three datasets combined, see Figure 1 a). The 
results are similar to those reported by comparable analysis of an independent sample (5), with high 
positive MS located in frontal and temporal cortical areas and high negative MS located in occipital 
and somatomotor cortex. This confirms the replicability of this anatomical distribution of regional MS 
in healthy individuals and is consistent with prior knowledge that primary cortex is more histologically 
differentiated than association cortex. 
We mapped the t-statistics for the case-control differences in regional MS at each cortical area (Figure 
1 b). A positive t-statistic means that MS increased in patients whereas a negative t-statistic means 
that MS decreased in patients. We found somewhat similar patterns of case-control difference across 
all three datasets, with increased regional MS in occipital and parietal areas of cortex, and decreased 
regional MS in frontal and temporal cortex, in patients with psychosis. The Dublin dataset showed the 
greatest number of cortical regions with significant differences between controls and patient (Figure 
S3). The convergence of case-control differences was quantified by the correlation of t-statistics 
between each pair of datasets. The Dublin dataset was significantly correlated with both the 
Maastricht and the COBRE datasets (r = 0.42, P < 0.001 and r = 0.47, P < 0.001, respectively), although 
the Maastricht and Cobre datasets were not significantly correlated with each other (r = 0.058, P = 
0.31), see Figure S4. These correlations were robust to a permutation test designed to account for 
spatial autocorrelation amongst neighboring cortical areas (12); see Supplemental Information (SI). 
 
 
We combined the P -values for case-control differences across all three datasets using Fisher’s method 
and corrected for multiple comparisons using the false discovery rate (FDR), to identify 18 cortical 
regions where MS was robustly and significantly different between groups (Figure 1 c). Decreased MS 
in patients was observed in 15 regions located in the superior frontal, caudal middle frontal, pre-
central, pars triangularis and superior temporal areas and increased MS was observed in 3 regions 
located in superior parietal and post-central areas (Table S2). 
There was a strong negative correlation between regional MS in the control subjects (averaged over 
all 3 datasets) and the case-control differences in regional MS (also averaged over all 3 datasets) 
(Figure 1 d). In other words, as suggested by visual comparison of the corresponding cortical maps, 
areas with highest positive MS in healthy controls tended to demonstrate the greatest decrease of MS 
in patients with psychosis; and, conversely, areas with highest negative MS in healthy controls had the 
greatest increase of MS in psychosis. 
To contextualise these results, we referred the maps of case-control difference in MS to two prior 
classifications of cortical areas: the von Economo atlas of cortex classified by cytoarchitectonic criteria 
(8); and the Yeo atlas of cortex classified according t o resting state networks derived from functional 
MRI (12). MS was significantly reduced in psychosis in von Economo class 2 (association cortex) on 
average over all three datasets. MS was also significantly r educed i n psychosis in the ventral 
attention, fronto-parietal and default mode networks of the Yeo atlas on average over all three 
datasets. These results are shown for the Dublin dataset in Figure S6 and for all three datasets in 
Tables S4 and S5. 
Gene expression related to morphometric similarity. We used PLS regression to identify patterns of 
gene expression, based on healthy post-mortem transcriptomic data from the Allen Human Brain Atlas 
(13), that were correlated with the anatomical distribution of case-control differences in MS. The PLS 
procedure finds the linear combination of weighted gene expression scores that has an anatomical 
distribution most closely similar to the cortical map of case-control differences in MS. 
The first PLS component explained 13% of the variance in the case-control MS diffrences, combining 
data from all three studies. This was a larger proportion of variance explained than expected by 
random weighting of gene expression (permutation test, P < 0.001). The cortical pattern of weighted 
gene expression represented by the first PLS component (Figure 2 b) looks similar to the map of mean 
case-control difference in MS (Figure 2 c). More formally, PLS1 gene expression weights were 
positively correlated with case-control MS differences in the Dublin study (r = 0.49, P < 0.001) and the 
Cobre study (r = 0.37, P < 0.001); but not with case-control differences in the Maastricht study (r = 
0.006, P = 0.94)(Figure 2 a). These positive correlations mean that positively weighted genes are over-
expressed in regions where MS is in-creased in patients with psychosis, and negatively weighted genes 
are over-expressed in regions where MS is decreased in patients (Figure 2 d). These results were 
robust to a spatial permutation test to account for spatial autocorrelation amongst neighboring 
cortical areas (12), see Table S8. 
Enrichment analysis of genes transcriptionally related to morphometric similarity. We focused first on 
the genes that were most negatively weighted on PLS1, because these are the genes that are normally 
highly expressed in brain areas where MS is reduced in patients with psychosis. We found 1110 genes 
with normalised PLS1 weights Z < −3 and mapped the network of known interactions between proteins 
coded by this gene set (14). The resulting protein-protein interaction (PPI) network had 341 proteins 
and 1022 edges, which is significantly more than the number of edges (802) expected by chance 
(permutation test, P < 1.0e − 13). We also tested the genes comprising the PPI network for significant 
GO enrichment of biological processes and enrichment of KEGG pathways, compared to a background 
of brain-expressed genes; see Figure 3 and Figure S7. Enriched biological processes included nervous 
system development, synaptic signaling and adenylate cyclase and related G-protein coupled receptor 
signalling pathways. There were two significantly enriched KEGG pathways: “neuroactive ligand-
receptor interaction” and “retrograde endocannabinoid signaling”, both of which were enriched in 
the most strongly interconnected cluster of genes in the PPI network (Fig. 3 b), as well as the biological 
process “adenylate-cyclase modulatingG-protein coupled receptor signaling pathway”. 
To test more formally for enrichment of genes linked to schizophrenia and other disorders, we used 
prior information about both gene transcription and sequence variation. Genes recently reported as 
over-expressed in post mortem brain tissue from patients with schizophrenia (15) were highly 
enriched among the set of genes that were negatively weighted on the first PLS component 
(permutation test, P < 10−4, before FDR correction), in comparison to a background of brain expressed 
genes (see Methods for details and SI for all results after FDR correction). In other words, genes that 
were up-regulated in post mortem brain tissue from patients with schizophrenia are normally over-
expressed in association cortical areas that have reduced MS in psychosis. We note that this result 
was not specific to abnormal gene expression in schizophrenia and there is substantial overlap 
between genes which are up/down regulated in schizophrenia and other psychiatric disorders (e.g. 
autistic spectrum disorders, ASD), see the SI for a discussion. 
Genes reported to show abnormal allelic variation in the most recent PGC genome wide association 
study (GWAS) of schizophrenia, or the CLOZUK sample (16), were not significantly enriched among the 
genes negatively weighted on PLS1 (P = 0.071, before FDR correction). However, schizophrenia risk 
genes from the DISEASES dataset (17), which combines results from gene association studies and text 
mining of biomedical abstracts, were significantly enriched a mong genes negatively weighted on PLS1 
(permutation test, P = 0.048, before FDR correction) and therefore normally over-expressed in 
association cortical areas where MS was reduced in psychosis. There was no significant enrichment of 
risk genes for several other disorders in the DISEASES dataset (Alzheimer’s disease, ASD, bipolar 
disorder) among the genes negatively weighted on PLS1, although risk genes for “mental depression” 
were significantly enriched (permutation t est, P =0.015, before FDR correction); see SI for details. 
For the genes which are positively weighted on PLS1 (Z > 3), the corresponding PPI network also shows 
significantly more interactions than expected by chance (P< 1.0e − 6), and is enriched for the biological 
process “nucleic acid metabolic process” but no KEGG pathways (see the SI and Figure S8 for details). 
Genes which are under-expressed post mortem in schizophrenia (15) are highly enriched among the 
genes positively weighted on PLS1, and therefore normally over-expressed in occipital and parietal 
cortical areas that have increased MS in psychosis. Genes reported to show abnormal allelic variation 
in schizophrenia in the PGC and CLOZUK GWAS studies (16), or in the DISEASES database, were not 
significantly enriched among the positively weighted PLS1 genes. 
Discussion. There are significant differences in MS between patients with psychosis and control 
subjects, which show re-markable reproducibility across three independent datasets, obtained with 
different subjects, locations, scanners and scanning parameters. Schizophrenia has been widely 
suggested to involve frontotemporal dysfunction (37) and dysconnectivity. Our results suggest that in 
patients with psychosis certain frontal and temporal regions are morphologically more differentiated 
from other regions in the brain than they are in control subjects, perhaps reflecting reduced 
connectivity given histological evidence that cytoarchitectonically similar regions are more likely to 
connect. The parietal lobe has also been implicated in schizophrenia, for example grey matter loss in 
child onset schizophrenia has been suggested to begin in the parietal lobe, but is less well studied than 
frontal and temporal regions (38, 39). Our results suggest that in patients the parietal lobe is less 
morphometrically distinct and more similar to other brain regions. These regional differences are 
strongest in the Dublin dataset, perhaps because the Dublin dataset has the highest mean image 
quality (as suggested by the images’ Euler numbers), underlining the importance of high-quality data 
for these analyses. The Dublin patients also have higher positive symptom scores than those in the 
Maastricht dataset, although not the Cobre dataset, see the SI. 
Genes which are over-expressed in regions of decreased MS in patients are significantly enriched for 
up-regulated schizophrenia genes identified by Gandal et al (15) from RNA sequencing experiments, 
as well as for the DISEASES list of schizophrenia-associated genes, but not the PGC+CLOZUK GWAS 
results. Meanwhile, genes which are over-expressed in regions of increased MS in patients are 
significantly enriched for down-regulated schizophrenia genes from (15). The enrichments of the 
Gandal genes are not specific to schizophrenia but are also observed in other psychiatric disorders, in-
line with the key result from (15) that shared molecular neuropathology exists between these 
disorders. In contrast, enrichment of the DISEASES schizophrenia gene list obtained via text mining, 
manually curated disease-gene associations and GWAS, exhibits a high level of specificity, with no 
enrichment of equivalent gene lists for ADHD, Alzheimer’s, disease, ASD, or bipolar disorder. The 
DISEASES gene list for ‘mental depression’ is significantly enriched, perhaps because patients with 
schizophrenia frequently suffer from depression (40). Methodological differences in diagnoses mean 
prevalence rates reported vary widely, but some reported rates are as high as 61% (41). The symptoms 
and genetic risk factors between the two disorders also overlap (40). 
The PPI network from genes which are over-expressed in regions of decreased MS is enriched for a 
number of relevant GO biological processes and KEGG pathways. Interestingly, the enrichments for 
the GO term “adenylate cyclase-modulating G-protein coupled receptor signaling pathway” and both 
significantly enriched KEGG pathways “neuroactive ligand-receptor interaction” and “retrograde 
endocannabinoid signaling” were concentrated in a tight cluster of the PPI network. This cluster 
includes multiple genes previously linked to schizophrenia from diverse lines of evidence across a 
number of genotypic and phenotypic levels. For example, polymorphisms of the DRD5, OPRM1 and 
CNR1 genes have each been associated with susceptibility to schizophrenia (22, 27, 28). Microarray 
screening and real-time PCR of lymphocyte gene expression identified decreased NPY1R and GNAO1 
i n individuals with schizophrenia compared to unaffected family controls (30). Centrally, mRNA 
studies in post-mortem brain tissue showed alterations in PTGER3, S1PR1, ITPR2, EDNRB, and SSTR2 
(15, 29, 31). Several genes in this cluster have also been implicated in therapeutic approaches to 
schizophrenia, including DRD4 which codes for the dopamine receptor 4 and is a target for drugs that 
treat schizophrenia and Parkinson disease. HTR1 codes for the serotonin 1A receptor (or 5-HT1A 
receptor) and the 5-HT1A receptor partial agonist properties of a number of atypical antipsychotics 
have been shown to enhance their clinical ecacy (42). NTSR1 is a high-anity receptor for neurotensin, 
which has been shown to selectively modulate dopaminergic neurotransmission and was reduced in 
the CSF and post-mortem brain tissue in schizophrenia (36, 43). Central administration of neurotensin 
also produced effects similar to those of atypical antipsychotics (44). Finally, ADRA2C is a candidate 
gene for schizophrenia because it binds clozapine, an atypical antipsychotic medication widely 
prescribed for treatment-resistant schizophrenia (23). We note that many of the above genes were 
not identified in most recent GWAS studies and therefore may not be implicated at the level of 
polymorphisms. Nevertheless, their involvement further down the causal pathway is still 
mechanistically revealing and potentially useful in practice. Indeed, the remarkable density of 
therapeutically relevant genes in this small cluster suggest that surrounding genes may deserve 
further attention. Overall, combining MRI data with whole-brain, whole-genome transcriptomic data 
from the AIBS provides an un-precedented opportunity to gain molecular insights into disease based 
on non-invasive, in vivo measurements alone. Subsequently mapping the PPI network linking the 
genes identified by our method provides a useful framework for understanding how previously 
implicated genes and proteins as well as a number of unreported proteins in their vicinity on the PPI 
network may interact to drive structural brain changes in schizophrenia. 
 
  
Some limitations of our analyses are as follows. The gene expression profiles were measured in six 
‘healthy’ postmortem adult brains (mean age = 43 years) and not in age-matched subjects or directly 
in patients with schizophrenia (such data are not currently available to our knowledge). Another 
limitation is that the sequencing experiments we use to label genes as up or down regulated were 
performed in regions of the parietal or prefrontal cortex (see (15) for details), although our 
neuroimaging results are for the whole brain. Genes which are e.g. down regulated in schizophrenia 
in a particular area of the cortex might be up regulated in other areas of the brain, however again a 
more comprehensive dataset with this type of information is not currently available to our knowl-
edge. Further work is needed to understand whether these effects might be important. Future work 
could also focus on which sMRI/DWI metrics provide the most powerful inputs to MS matrices. Here 
we used 7 metrics from (5) which were available in the datasets studied, although this choice may not 
be optimal and alternative imaging protocols could pro-vide opportunities to include additional, more 
informative measures. 
Materials and Methods 
Data. We used two PSYSCAN legacy datasets with MRI images rom patients with psychosis and control 
subjects- the Maastricht GROUP dataset from an MRI study in Maastricht led by the GROUP 
consortium (45) and the Dublin dataset which was acquired and scanned at the Trinity College Institute 
of Neuroscience as part of a Science Foundation Ireland-funded neuroimaging genetics study (“A 
structural and functional MRI investigation of genetics, cognition and emotion in schizophrenia"), and 
the publicly available Cobre dataset (46). 
Dataset details and demographics are given in the SI. There are group differences in sex in both the 
Maastricht and Dublin datasets (patients are more likely than controls to be male) and in the Dublin 
data there is also a group difference in age (with patients approximately 10 years older than controls 
on average). Therefore we control for age, sex and an interaction term in all analyses. Whilst most 
patients have a diagnosis of schizophrenia, some patients have other forms of psychosis, all diagnosed 
using DSM-IV criteria. Subjects with a diagnosis of major depressive disorder or bipolar disorder were 
excluded. All subjects were man-386 ually checked for motion artifacts and subjects with large motion  
artifacts were excluded. The Euler number, which quantifies image 388 quality (47), did not vary 
between groups in any of the datasets. The Euler number results suggest that the Dublin dataset has 
the highest image quality, whilst the Maastricht dataset has the lowest image quality, see the SI. 
MRI pre-processing. T1w MPRAGE and DWI images were pre-processed using a pipeline based on 
scripts from (8). Briefly, we use the reconall (48–51) and tracall (52) commands from FreeSurfer 
(version 6.0). Following (5), the surfaces were then parcellated using an atlas with 308 cortical regions, 
derived from the Desikan-Killiany atlas and designed so that different regions have similar sizes (53, 
54). For each of these regions we extract grey matter volume, surface area, cortical thickness, 
Gaussian curvature, mean curvature, and fractional anisotropy (FA) and mean diffusivity (MD) from 
the diffusion tensor fit. 
Having parcellated the sMRI images to obtain the 7 regional measures listed above, we construct MS 
matrices as outlined by (5).  Briefly, we Z-score the regional measures and correlate the vector of 
measures for each region between regions, to obtain individual 406 MS matrices with 308 × 308 
elements. 
MS analyses. For each subject we calculate the mean MS and fit a linear regression model with age, 
sex and an age/sex interaction term as covariates to calculate whether there is a significant effect of 
group on mean MS. We then calculate regional MS values and fit a linear model for each regional MS 
value individually, obtaining a t-statistic and corresponding p-value for the effect of group on each 
region’s MS. A strong positive t-statistic means that MS increases in patients and vice versa. We 
combine the regional P-values from the three datasets using Fisher’s method, to give a single P-value  
per region, then perform an FDR correction across regions and search for regions with P < 0.05. The 
results were visualized on 418 the surface of the average brain using (55). 
To assess whether MS shows differences in particular Yeo net- works/von Economo classes we first 
average the regional MS values across all regions in a given network. Then we fit a linear model as 
above to obtain a t-statistic and P-value. We use Fisher’s method to combine the P-values from all 
three datasets and perform an FDR correction for multiple comparisons across the 7 networks. 
Transcriptomic analysis. We used a transcriptomic dataset provided by the AIBS, with gene expression 
measurements in 6 post-mortem ‘healthy’ adult brains (13) (http://human.brain-map.org), aged 24-
57. Each tissue sample was assigned to an anatomical structure using the AIBS MRI data for each 
donor, as described previously (56). Due to the similarity of gene expression between hemispheres, 
the AIBS only sampled two of the six donors in the right hemisphere (all six subjects include data from 
the left hemisphere). To increase the number of AIBS samples per cortical region, all samples were 
pooled between bilaterally homologous cortical areas. Regional expression levels were compiled to 
form a (308 × 20,647) regional transcription matrix (56). Since the AIBS dataset only includes the right 
hemisphere for two subjects, in our analyses relating gene expression values to MRI data we only 
include edges within the left hemisphere. We use PLS to relate the regional MS patient/control 
differences (the response variables) to the gene expression measurements (the predictor variables). 
The output PLS components are the linear combinations of the weighted gene expression scores that 
are most strongly correlated with the patient/control MS differences. We use t-statistics from all three 
datasets as response variables. 
We calculate PPI networks from the genes with PLS1 weight Z > 3 or Z < −3, using STRING (14). We use 
the ‘highestconfidence’ minimum required interaction score of 0.9. Results were robust to changing 
the required interaction score and the Z-score threshold. We use the P-value output by STRING to 
assess whether the PPI networks we obtain have more interactions than expected by chance. We use 
DAVID (57, 58) to calculate enrichments of KEGG pathways and GO enrichments of biological 
processes for genes with Z > 3 or Z < −3, using a background gene list of 15745 brain-expressed genes. 
The background gene list is provided in supplement and was calculated by excluding probes which did 
not exceed the background noise in the AHBA dataset (intensity based filtering), as described by (59). 
We used code from (59), with options.probeSelections = ‘maxIntensity’, inline with the maximum 
intensity approach used to derive our gene expression values (11). To quantify enrichment of the 
significantly up/down regulated Gandal genes (15) and the ‘DISEASES’ gene list (17), we calculate their 
median position in PLS1 and compare to 10000 lists of randomly selected brain-expressed background 
genes, as in (5). 
Summary statistics from a meta-analysis of GWAS results from CLOZUK and independent PGC data 
were obtained from (16). To calculate enrichment for association of genes reported to show abnormal 
allelic variation in PLS1, we performed a gene set analysis using the software MAGMA v1.07b (60). 
First, gene-wide P values were calculated by combining the P-values of all SNPs inside genes, using a 
window of 35 kb upstream and 10 kb downstream of each gene to capture SNPs in approximate 
regulatory regions (61). We then performed one-tailed competitive gene set analysis and gene 
property analysis, using the same background list of brain-expressed genes as above. 
Data and code availability. All code and processed data? used for the analyses will be made available 
on GitHub on publication. 
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